近亿元融资！医用水凝胶公司完成C轮

Company Overview - Shanghai Ruining Biotechnology Co., Ltd. completed nearly 100 million RMB in Series C financing, led by Fudan Science and Technology and Qiming Venture Partners, with Haoyue Capital as the exclusive financial advisor. The funds will be used for clinical advancement and commercialization of core products [2] - The company was established in 2018 and is headquartered in Shanghai, focusing on medical hydrogel technology platforms for innovative medical devices in major clinical scenarios such as tumor treatment [5] Products and Technology - The main products include: - Respacio® absorbable isolation hydrogel for tumor radiotherapy protection, which has completed domestic clinical trials and is included in the National Medical Products Administration's special review procedure for innovative medical devices. It has received breakthrough medical device designation from the FDA and has submitted an application for CE certification in Europe [5] - Tumor embolization hydrogel for the treatment of hypervascular malignant tumors, which is also included in the special review procedure [7] - Uterine adhesion prevention hydrogel, currently in the clinical enrollment stage [7] - The medical hydrogel technology platform is applicable in areas such as tumor radiotherapy protection, tumor interventional embolization, uterine adhesion prevention, tissue filling, tissue regeneration, and drug delivery [8] Financing History - The financing history of the company includes: - Series C on February 28, 2025, raising approximately 100 million RMB, led by Qiming Venture Partners and Fudan Science and Technology [10] - Series B on January 24, 2024, also raising approximately 100 million RMB [10] - Series A on September 23, 2022, and earlier rounds including angel investments [10] Patent Information - The company has several patents, including: - A rapid-dissolving hydrogel reagent kit, authorized on August 22, 2023 [11] - A chitosan-polyethylene glycol-lithium diatomite composite hydrogel, published on August 8, 2024 [11] - A drug-loaded embolization microsphere, authorized on December 28, 2022 [11]